Transcode Therapeutics, Inc.
No enriched coverage for $RNAZ in the last 7 days.
No SEC Form 4 filings for $RNAZ in the last 30 days.
See all $RNAZ insider activity →Transcode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement As previously disclosed by TransCode Therapeutics, Inc. (the “Company”) in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 7, 2026, the Company entered into a Standby Equity P
Transcode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Other Events. Exhibit 99.1 TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors · I
TransCode Therapeutics (RNAZ) announced patent advancements in Australia and Japan for its RNA-based cancer therapy platform. The Australian patent covers siRNA delivery for cancer treatment, while the Japanese patent focuses on RNA-based immunomodulation. These developments strengthen the company's global IP portfolio and support its lead therapeutic candidate, TTX-MC138.
Recent RNAZ coverage spans market movers, corporate actions and technology.
The financing waiver and prepayment improve liquidity and may support the share price.
Positive Phase 1a results likely lift sentiment and attract speculative buying.
The patent approvals strengthen the company's IP portfolio but have limited immediate financial impact.
The departure of the CFO and related severance terms may cause short‑term stock volatility and raise questions about financial leadership continuity.
Strong pre‑market rally suggests speculative buying.
AlphAI scores every news story that mentions RNAZ with an AI model for sentiment and relevance, and aggregates insider trades from Transcode Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Transcode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement As previously disclosed by TransCode Therapeutics, Inc. (the “Company”) in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 7, 2026, the Company entered into a Standby Equity P
1 min readTranscode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Other Events. Exhibit 99.1 TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors · I
2 min readTransCode Therapeutics (RNAZ) announced patent advancements in Australia and Japan for its RNA-based cancer therapy platform. The Australian patent covers siRNA delivery for cancer treatment, while the Japanese patent focuses on RNA-based immunomodulation. These developments strengthen the company's global IP portfolio and support its lead therapeutic candidate, TTX-MC138.
1 min readTranscode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Director On September 1
1 min readSeveral biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.
1 min readTenon Medical (TNON) shares rose 80% after-hours with no specific news, reporting Q2 revenue of $1.3M (up 127% YoY) and a net loss of $4.1M. BioVie (BIVI) gained 55% after positive Phase 2 trial results for its Parkinson's drug. Edesa Biotech (EDSA) advanced 7% after announcing Phase 2 trial preparations for vitiligo treatment. TransCode (RNAZ) and HCW Biologics (HCWB) also saw after-hours gains on trial updates.
6 min readRedChip Companies says it will air interviews on Bloomberg TV and CNBC featuring Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ). Virax CEO James Foster discusses post-fiscal 2026 balance sheet and Nasdaq bid compliance, plus ImmuneSelect supply talks. Transcode CEO Philippe Calais covers TTX-MC138 Phase 2a progress in ctDNA+ colorectal cancer.
2 min readTranscode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001829635 0001829635 2026-07-20 2026-07-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readBiotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.
6 min readBiotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.
7 min read
